TRIAL DETAIL
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 03/01/2009 |
Age of Trial (yrs) 16.1 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor + mTOR inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
PIM4604g |
|||
Sponsor: |
Genentech |
|||
Patient Contact: |
Please reference Study ID Number: PIM4604g 888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
3322 West End Avenue |
Nashville |
TN |
37203 |
USA |
|
Downs Rd |
Sutton |
Surrey |
SM2 5PT |
UK |
|
5841 S. Maryland Ave |
Chicago |
IL |
60637 |
USA |
|
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
New York |
NY |
10065 |
USA |